本研究进行了文献计量文献分析，以探索 2019 年至 2023 年卵巢癌免疫治疗的趋势。在 Web of Science 核心合集数据库中进行了广泛的在线文献检索，以识别与“免疫治疗趋势”相关的英文文章和评论和“卵巢癌”。使用 VOSviewer 进行统计分析，同时可视化和比较国家、机构和期刊。我们的研究结果突出了 118 个国家的贡献，其中以中华人民共和国为首，贡献了 3,167 份；德国紧随其后，有 558 条，意大利有 547 条。在 2019 年至 2023 年期间发表的所有出版物中，“前沿免疫学”的出版物最多，共有 546 条记录，其次是“癌症”，“肿瘤学前沿”是最受依赖的类别。每年的发表趋势在 2022 年之前一直呈增长趋势，但随着 2019 年至 2022 年之间出现高被引论文的高峰而大幅下降。我们的文献计量分析不仅描绘了卵巢癌免疫治疗研究的演变，还为推进科学进步提供了可行的见解。通过确定新兴趋势和关键领域，未来的研究可以战略性地增强卵巢癌患者的治疗策略和结果。版权所有 © 2024 Shaie、Sihan、Yuli、Mengfei、Renqian 和 Yan。

This study conducts a bibliometric literature analysis to explore trends in immunotherapy for ovarian cancer from 2019 to 2023.An extensive online literature search was conducted in the Web of Science Core Collection database to identify English-language articles and reviews related to "trends in immunotherapy", and "ovarian cancer". statistical analysis was performed using VOSviewer to visualize and compare nations, institutions, and journals simultaneously.Our findings highlight contributions by 118 nations, led by the People's Republic of China with 3,167 contributions; Germany followed with 558 and Italy having 547. Of all publications made between 2019-2023, "Frontiers Immunology" had the most publications with 546 total records followed by "cancers ", and "frontiers in oncology" being the most heavily relied upon categories. Annually publication trends increased until 2022 but then declined considerably as a peak of highly-cited papers occurring between 2019 and 2022.Our bibliometric analysis not only maps the evolution of immunotherapy research in ovarian cancer but also provides actionable insights for advancing scientific progress. By identifying emerging trends and key areas, future research can strategically enhance treatment strategies and outcomes for ovarian cancer patients.Copyright © 2024 Shaie, Sihan, Yuli, Mengfei, Renqian and Yan.